Method of predicting sensitivity to prostate cancer therapy

摘要

A treatment for prostate cancer using cyclin-dependent kinase inhibitors (CKIs) and a method of determining patient sensitivity to such CKIs is provided. The effects of cyclin-dependent kinase inhibitors on the survival of prostate cancer cells was examined. Roscovitine, R-roscovitine, and CGP74514A were shown to induce the apoptosis of LNCaP and LNCaP-Rf cells, both of which express wild-type p53. The cyclin-dependent kinase inhibitors of the present invention induce the mitochondria-mediated apoptosis of prostate cancer cells by a dual mechanism: p53 accumulation and XIAP depletion.

主权项

1. A method for predicting sensitivity of a subject to prostate cancer treatment with a purine analog comprising:
obtaining a tumor sample from the subject; obtaining an expression level of p53 in the tumor sample; comparing the expression level of p53 from the tumor sample to a predetermined control expression level; determining a therapeutic response based on comparison of the expression level of p53 in the tumor sample to the predetermined control expression level wherein an increased expression level of p53 in the tumor sample as compared to the predetermined control expression level is indicative of a favorable therapeutic response; and administering a therapeutically effective amount of the purine analog to the subject if the comparison is indicative of the favorable therapeutic response; wherein the purine analog is a CDK inhibitor selected from the group consisting of CGP74514A, roscovitine and R-roscovitine.